When In Vitro Data Can Replace In Vivo Studies in ANDA Submissions

Understanding In Vitro and In Vivo Requirements

Generic drug applicants must demonstrate bioequivalence to a Reference Listed Drug (RLD) as part of an Abbreviated New Drug Application (ANDA). This bioequivalence can be shown through either:

• In vivo data — typically from pharmacokinetic (PK) studies in human volunteers
• In vitro data — such as comparative dissolution testing, where specific conditions are met

The U.S. FDA allows for waiver of in vivo studies in certain cases, especially for immediate-release solid oral dosage forms meeting Biopharmaceutics Classification System (BCS) criteria. This is commonly referred to as a biowaiver.

This article outlines when and how in vitro data may substitute in vivo studies in ANDA submissions, what regulatory guidance applies, and how to prepare a robust data package.

Biopharmaceutics Classification System (BCS) Overview

The BCS categorizes drugs based on solubility and permeability:

In general, Class I and Class III drugs may be eligible for biowaivers if rapid dissolution and other conditions are met. FDA’s Product-Specific Guidances (PSGs) often clarify when in vitro data is sufficient.

Dissolution Testing and the f₂ Similarity Factor

Comparative dissolution is key to in vitro bioequivalence. Testing is conducted in:

• pH 1.2 (simulated gastric fluid)
• pH 4.5 (simulated intestinal fluid)
• pH 6.8 (phosphate buffer)

A minimum of 12 units of test and reference products must be tested using USP Apparatus I or II.

Results are analyzed using the f₂ similarity factor, calculated as:

f₂ = 50 × log {[1 + (1/n) ∑(Rt – Tt)²]⁻⁰·⁵ × 100}
        

Where:

• n = number of time points
• Rt and Tt = % dissolved of reference and test at time t

An f₂ value between 50 and 100 indicates similarity.

Biowaiver Justification, Case Examples, and Regulatory Considerations

Justifying a Biowaiver in ANDA Submissions

To seek a biowaiver, the ANDA applicant must provide detailed evidence that the test product meets the criteria for waiver of in vivo studies. This includes:

• BCS classification evidence (solubility and permeability studies or literature)
• Formulation sameness or similarity to the RLD
• Manufacturing process control and batch uniformity
• Comparative dissolution data at three pH levels

For BCS Class III drugs, additional criteria include demonstrating excipient sameness (Q1/Q2 similarity) and robust control of manufacturing variability.

In Vitro-In Vivo Correlation (IVIVC)

In some cases, in vitro data can be correlated to in vivo absorption using IVIVC models. While rarely required in ANDA submissions, IVIVC can strengthen biowaiver justification and support formulation bridging for post-approval changes.

IVIVC is most applicable to modified-release dosage forms and involves plotting in vitro release against in vivo absorption to determine Level A, B, or C correlations.

Real-World Example: BCS Class I Generic Approval

A sponsor developing a generic for a BCS Class I antihypertensive drug submitted:

• Evidence of high solubility across pH 1–7.5
• Human permeability data from published literature
• Comparative dissolution f₂ ≥ 65 at all pH levels

FDA accepted the biowaiver, and the product was approved without an in vivo PK study.

In Vivo Study Requirements for Non-Biowaivable Products

For BCS Class II and IV products or those with narrow therapeutic index (NTI), FDA typically requires in vivo studies. These include:

• Single-dose crossover design in healthy volunteers
• Fed and fasting conditions, if required
• PK endpoints: C_max, AUC_0–t, AUC_0–∞
• Statistical confidence interval (CI) of 80–125%

FDA guidance is available in the relevant PSGs and must be strictly followed.

Regulatory Pitfalls and Deficiencies

Common mistakes in biowaiver requests include:

• Inadequate f₂ justification (less than 12 units tested)
• Mismatch in formulation composition (Q1/Q2 differences)
• Incomplete permeability classification evidence
• Use of outdated dissolution methods or unvalidated equipment

These issues can lead to FDA issuing a Complete Response Letter (CRL), delaying approval and requiring additional in vivo data.

Role of Product-Specific Guidances (PSGs)

The FDA regularly updates its PSGs, which clarify whether in vitro-only data is acceptable. Applicants should always reference the latest guidance on:

• Study design requirements
• Waiver eligibility
• Dissolution media and apparatus

See the full list at FDA Product-Specific Guidances.

Conclusion: Strategic Use of In Vitro Data

Leveraging in vitro data in place of in vivo studies can significantly reduce development costs and timelines for generic drug sponsors. However, a successful biowaiver requires scientific justification, regulatory alignment, and rigorous testing.

In vitro strategies are especially beneficial for BCS Class I and III drugs. Applicants must ensure compliance with FDA’s biowaiver guidance and PSGs to avoid unnecessary rejections or clinical study requirements.

Strategic Guide to Obtaining Waivers for In Vivo Bioequivalence Studies

Introduction: Why Waive In Vivo BE Studies?

In vivo bioequivalence (BE) studies are time-consuming, expensive, and sometimes unnecessary—particularly for drugs that meet specific regulatory criteria for waivers. Regulatory agencies like the FDA and EMA allow applicants to bypass in vivo BE studies by providing strong in vitro data for certain types of drug products, most notably those that fall under the Biopharmaceutics Classification System (BCS) Class I.

Waiving in vivo studies requires a solid regulatory strategy, precise documentation, and deep understanding of the guidelines involved. This article breaks down the conditions under which BE waivers may be granted, the supporting documentation needed, and how to align your submission with regulatory expectations across regions.

Regulatory Framework for BE Waivers

Both the U.S. FDA and European Medicines Agency (EMA) have clear but slightly differing guidelines when it comes to waiving in vivo studies:

• FDA: Provides guidance on BCS-based biowaivers, emphasizing solubility, permeability, and dissolution similarity.
• EMA: Allows biowaivers under the Guideline on the Investigation of Bioequivalence (CPMP/EWP/QWP/1401/98 Rev. 1), focusing on comparative dissolution and justification for the class of drug.

Regulators accept waivers primarily for immediate-release oral solid dosage forms containing highly soluble and highly permeable APIs.

Understanding BCS Classes and Their Relevance

The Biopharmaceutics Classification System categorizes drugs into four classes based on solubility and permeability:

• Class I: High solubility, high permeability → Most likely to qualify for waiver
• Class II: Low solubility, high permeability → Waiver generally not accepted
• Class III: High solubility, low permeability → EMA may allow waivers with strong justification
• Class IV: Low solubility, low permeability → Waiver not accepted

To qualify for a BCS-based biowaiver, the product must belong to Class I (or Class III under EMA with strong data) and meet other requirements such as rapid dissolution, dosage proportionality, and identical formulation to the reference product.

Key Waiver Eligibility Criteria

Below are common regulatory expectations to support an in vivo BE waiver request:

• Complete characterization of solubility across physiological pH range (1.0–7.5)
• Permeability data from validated models (e.g., human jejunal perfusion, Caco-2)
• Rapid and similar in vitro dissolution profile in 3 media (pH 1.2, 4.5, and 6.8)
• Dosage form identical to reference in terms of excipient type and level
• Absence of narrow therapeutic index (NTI) classification
• Formulation stability and absence of significant food effect

Sample Dissolution Comparison Table

The following dummy table demonstrates what a typical comparative dissolution data table might look like:

Similarity factor (f2) should be calculated and reported. A value ≥50 is typically considered acceptable.

EMA vs FDA: Biowaiver Differences

• Permeability Acceptance: FDA accepts in vitro models; EMA prefers in vivo permeability data
• Class III Waiver: EMA may consider it; FDA does not, except in rare pediatric cases
• Excipient Tolerance: EMA is stricter regarding differences in excipient composition
• Food Effect: FDA requires additional evidence if food affects absorption

For global regulatory alignment, always consult the specific regional guideline. A good starting point is the CTRI Registry to review local requirements and previous biowaiver-approved studies.

Submission Strategy for Biowaiver Requests

Include the following documents in your CTD dossier when requesting a BE waiver:

• Module 2.5: Clinical Overview (justify waiver and reference BCS class)
• Module 3.2.P: Pharmaceutical Development (excipient composition, dissolution data)
• Module 5.3.1: Comparative Dissolution and Permeability Study Reports
• Cover letter highlighting the waiver request with scientific rationale

Ensure all reports include validated methods, version history, and statistical evaluations.

Case Study: Biowaiver for a Generic Antifungal

A company seeking approval for a generic fluconazole 150 mg capsule filed a waiver based on:

• BCS Class I classification
• Dissolution similarity with f2 > 60 in all three media
• Identical formulation and no food effect

The waiver was accepted by both FDA and EMA, avoiding the need for a costly clinical trial and reducing approval time by over 4 months.

Best Practices and Common Mistakes to Avoid

Do:

• Justify everything with data
• Perform robust comparative dissolution studies
• Include complete solubility profiles across pH spectrum
• Stay updated on evolving EMA and FDA guidelines

Don’t:

• Assume Class I equals automatic waiver
• Ignore variability between test and reference formulations
• Rely on outdated permeability models
• Submit dissolution data without similarity factor

Conclusion: Smart Submission Planning for Waivers

Regulatory waivers for in vivo BE studies can significantly streamline the drug development process—but only if handled meticulously. A proactive and evidence-based approach—rooted in BCS science, comparative data, and regulatory familiarity—can help you obtain approval faster while ensuring compliance and product quality. Whether targeting the FDA, EMA, or both, always prioritize data integrity and regulatory alignment.